Tarsus Pharmaceuticals(US:TARS)2026-02-23 22:32Financial Data and Key Metrics Changes - In 2025, Tarsus Pharmaceuticals achieved over $450 million in full-year net sales, with Q4 net product sales reaching $151.7 million at a gross net discount of 44% [4][22] - The company ended the year with approximately $418 million in cash, cash equivalents, and marketable securities, providing financial flexibility for growth [22] - For 2026, Tarsus expects net product sales in the range of $670 million to $700 million, representing an annual growth of over $230 million and 50% at the midpoint of guidance [23] Business Line Data and Key Metrics Changes - XDEMVY, the company's primary product, is now profitable and growing, with significant market penetration potential among the estimated 25 million Americans living with Demodex blepharitis [8][9] - The company plans to add approximately 15-20 key account leaders to enhance sales force effectiveness in 2026 [10] Market Data and Key Metrics Changes - Tarsus has over 90% coverage across commercial Medicare and Medicaid, which is expanding the funnel of diagnosed and treated patients [10] - The company has seen a shift in eye care professionals' (ECPs) practice behavior, with many now screening for Demodex blepharitis in patients with other eye conditions [9][10] Company Strategy and Development Direction - Tarsus aims to build on the success of XDEMVY by applying its proven development and commercial playbook to new programs, including TP-04 for ocular rosacea and TP-05 for Lyme disease prevention [5][6] - The company plans to expand its pipeline by targeting one to two new programs per year, allowing for focused growth and responsible capital allocation [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of XDEMVY, citing strong fundamentals and a growing base of prescribers [8][9] - The company anticipates typical first-quarter seasonality to impact growth, with expectations for a strong second quarter and robust growth in the fourth quarter of 2026 [23][24] Other Important Information - Tarsus is actively pursuing global regulatory approvals for TP-03, with potential approvals expected in Europe and Japan in 2027 [20][21] - The company has welcomed David Pyott to its board, enhancing its leadership in the biopharmaceutical industry [6][7] Q&A Session Summary Question: Can you provide more detail on expectations beyond Q1 for the $670 million-$700 million guidance? - Management indicated that Q1 is expected to be flat to slightly down due to typical seasonal dynamics, with a strong growth anticipated in Q2 [32][33] Question: What is driving the increased peak sales target to over $2 billion? - The increase is attributed to a growing prescriber base and deeper utilization among top-tier prescribers, along with continued flawless execution in commercial efforts [42][43] Question: Can you elaborate on the DTC campaign and its ROI? - The DTC campaign has performed exceptionally well, achieving positive ROI earlier than expected, and management plans to maintain the $80 million spend while also investing in the sales force [46][48] Question: What are the expected costs for the pivotal studies for ocular rosacea and Lyme disease? - The ocular rosacea study is expected to cost between $7 million and $10 million, while the Lyme disease study is projected to cost between $25 million and $30 million [75][76] Question: What are the current prescribing trends between ophthalmologists and optometrists? - The prescribing dynamics show strong growth in both segments, with approximately 40% of the core target prescribing weekly [79]